metastasis via the node status often does not work, surprising clinicians. The Solution: Mestastop has identified the gaps as to why anti-metastasis drug discovery failed and has created three proprietary platforms integrating cell biology, genetic engineering, machine learning, animal pharmacology and clinical sampling that do the following: 1. Identifies the rate-limiting steps of metastasis, thereby discovering novel first-in-class targets 2. Screening platform to identify compounds that abrogate the rate-limiting steps 3. Screening platform that identifies the effect of approved drugs on the process of metastasis 4. Predicting the metastatic probability of a treatment-naive primary tumour patient with no second lesion